HEP C
TODAY'S HEADLINES
A new US Congressional report about the price of hepatitis C drug Sovaldi, along with a new class action lawsuit against Blue Cross Blue Shield involving Harvoni coverage, are the latest in a series of controversies surrounding the 2 drugs. Read more |
|
FDA has approved elotuzumab (Empliciti, Bristol-Myers Squibb and AbbVie) as combination therapy with lenalidomide (Revlimid, Celgene) and dexamethasone (ERd) in people with multiple myeloma who have received 1 to 3 prior medications. Read more
|
CONTINUING EDUCATION
November 2015
Recognition of drug-induced pulmonary disease and management of idiopathic pulmonary fibrosis
Session code: 15DT36-KXF58
This month's CE activity is part of the CPE series, "Medication Therapy Management for the Patient with Respiratory Disease." From April 2015 through December 2015, pharmacists can earn up to 18 hours of CPE credit with 9 monthly knowledge-based activities from the University of Connecticut School of Pharmacy and Drug Topics.
|
|
|
